Physician profile

James H Thrall

Nuclear Radiology · Boston, MA

NPI 1659352904

$1,588,603.32

in general payments reported to CMS, 2019-2025

1 company · $300K in 2025

The $300K reported for 2025 was more than what 99% of Nuclear Radiology providers received nationally (typical 2025 total: $145).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$863,279.03
Travel and Lodging$23,120.54
Food and Beverage$5,028.70

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Lantheus Medical Imaging, INC. $1,588,603.32 2019-2025

Research and ownership

$5,524,376.95 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

James H Thrall

$1,588,603.32

in general payments reported 2019-2025

Years
2019-2025
Top company
Lantheus Medical Imaging, INC.
Context
The $300K reported for 2025 was more than what 99% of Nuclear Radiology providers received nationally (typical 2025 total: $145).

https://glasscript.com/doctor/638050/james-h-thrall

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.